Calprotectin in spondyloarthritis: A systematic review and meta-analysis
•Serum and fecal calprotectin were increased in SpA patients.•Level of serum or fecal calprotectin was associated with CRP, ESR, BASDAI and BASFI.•Serum and fecal calprotectin could act as biomarkers for SpA. There is still an unmet need for a simple and reliable biomarker for diagnosis and disease...
Gespeichert in:
| Veröffentlicht in: | International immunopharmacology 2020-11, Vol.88, p.106948-106948, Article 106948 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 106948 |
|---|---|
| container_issue | |
| container_start_page | 106948 |
| container_title | International immunopharmacology |
| container_volume | 88 |
| creator | Ma, Yubo Fan, Dazhi Xu, Shanshan Deng, Jixiang Gao, Xing Guan, Shiyang Pan, Faming |
| description | •Serum and fecal calprotectin were increased in SpA patients.•Level of serum or fecal calprotectin was associated with CRP, ESR, BASDAI and BASFI.•Serum and fecal calprotectin could act as biomarkers for SpA.
There is still an unmet need for a simple and reliable biomarker for diagnosis and disease activity of spondyloarthritis. Recent studies indicated that calprotectin could act as a biomarker for spondyloarthritis. Therefore, this systematic review and meta-analysis aims to evaluate the levels of serum and fecal calprotectin in spondyloarthritis and the associations with disease activity.
PubMed, Web of Science and Cochrane Library were comprehensively searched from inception to July 1st, 2019. The pooled standard mean differences (SMDs) were used to estimate the differences of the levels of serum and fecal calprotectin between spondyloarthritis patients and controls. Spearman correlation coefficients were used for evaluating the associations between the levels of serum and fecal calprotectin and disease activity of spondyloarthritis patients. The use of fixed-effect or random-effects model depended on heterogeneity.
Among 257 searched studies, 20 studies were finally included for analysis. Serum and fecal calprotectin were both significantly increased in spondyloarthritis patients compared to matched controls (SMD = 1.49, 95% CI = 0.91 to 2.08; SMD = 2.29, 95% CI = 0.25 to 4.33). The pooled correlation coefficients between serum or fecal calprotectin and CRP, ESR, BASDAI and BASFI were 0.353, 0.228, 0.225, 0.131 and 0.185, 0.163, 0.280, 0.196 respectively.
Our study indicated that serum and fecal calprotectin were significantly increased in spondyloarthritis patients, and associated with disease activity. Serum and fecal calprotectin were potential biomarkers for the diagnosis and disease activity of spondyloarthritis. |
| doi_str_mv | 10.1016/j.intimp.2020.106948 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2440664901</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1567576920319548</els_id><sourcerecordid>2440664901</sourcerecordid><originalsourceid>FETCH-LOGICAL-c367t-a23fa5375ca8288d396dde5ee849b9935aae3ddc80d50934bf6734c2aa5874ea3</originalsourceid><addsrcrecordid>eNp9kEtLAzEQgBdRsD7-gYcFL162Jpu3B0GKLxC86DlMkymm7KMmqdJ_b8p68iAMzDB8M8x8VXVByZwSKq_X8zDk0G_mLWn3LWm4PqhmVCvdUEXEYamFVI1Q0hxXJymtCSl9TmfV0wK6TRwzuhyGukTajIPfdSPE_BFDDummvqvTLmXsIQdXR_wK-F3D4OseMzQwQLdLIZ1VRyvoEp7_5tPq_eH-bfHUvLw-Pi_uXhrHpMoNtGwFginhQLdae2ak9ygQNTdLY5gAQOa908QLYhhfrqRi3LUAQiuOwE6rq2lvufpziynbPiSHXQcDjttkW86JlNwQWtDLP-h63MZy755SWrfUcFkoPlEujilFXNlNDD3EnaXE7vXatZ302r1eO-ktY7fTGJZni5Jokws4OPQhFpnWj-H_BT-Bd4WU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2478821946</pqid></control><display><type>article</type><title>Calprotectin in spondyloarthritis: A systematic review and meta-analysis</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Ma, Yubo ; Fan, Dazhi ; Xu, Shanshan ; Deng, Jixiang ; Gao, Xing ; Guan, Shiyang ; Pan, Faming</creator><creatorcontrib>Ma, Yubo ; Fan, Dazhi ; Xu, Shanshan ; Deng, Jixiang ; Gao, Xing ; Guan, Shiyang ; Pan, Faming</creatorcontrib><description>•Serum and fecal calprotectin were increased in SpA patients.•Level of serum or fecal calprotectin was associated with CRP, ESR, BASDAI and BASFI.•Serum and fecal calprotectin could act as biomarkers for SpA.
There is still an unmet need for a simple and reliable biomarker for diagnosis and disease activity of spondyloarthritis. Recent studies indicated that calprotectin could act as a biomarker for spondyloarthritis. Therefore, this systematic review and meta-analysis aims to evaluate the levels of serum and fecal calprotectin in spondyloarthritis and the associations with disease activity.
PubMed, Web of Science and Cochrane Library were comprehensively searched from inception to July 1st, 2019. The pooled standard mean differences (SMDs) were used to estimate the differences of the levels of serum and fecal calprotectin between spondyloarthritis patients and controls. Spearman correlation coefficients were used for evaluating the associations between the levels of serum and fecal calprotectin and disease activity of spondyloarthritis patients. The use of fixed-effect or random-effects model depended on heterogeneity.
Among 257 searched studies, 20 studies were finally included for analysis. Serum and fecal calprotectin were both significantly increased in spondyloarthritis patients compared to matched controls (SMD = 1.49, 95% CI = 0.91 to 2.08; SMD = 2.29, 95% CI = 0.25 to 4.33). The pooled correlation coefficients between serum or fecal calprotectin and CRP, ESR, BASDAI and BASFI were 0.353, 0.228, 0.225, 0.131 and 0.185, 0.163, 0.280, 0.196 respectively.
Our study indicated that serum and fecal calprotectin were significantly increased in spondyloarthritis patients, and associated with disease activity. Serum and fecal calprotectin were potential biomarkers for the diagnosis and disease activity of spondyloarthritis.</description><identifier>ISSN: 1567-5769</identifier><identifier>EISSN: 1878-1705</identifier><identifier>DOI: 10.1016/j.intimp.2020.106948</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Ankylosing spondylitis ; Arthritis ; Biomarkers ; Calprotectin ; Correlation coefficient ; Correlation coefficients ; Diagnosis ; Feces ; Heterogeneity ; Inflammatory diseases ; Meta-analysis ; Rheumatic diseases ; Spondyloarhritis ; Systematic review</subject><ispartof>International immunopharmacology, 2020-11, Vol.88, p.106948-106948, Article 106948</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright Elsevier BV Nov 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c367t-a23fa5375ca8288d396dde5ee849b9935aae3ddc80d50934bf6734c2aa5874ea3</citedby><cites>FETCH-LOGICAL-c367t-a23fa5375ca8288d396dde5ee849b9935aae3ddc80d50934bf6734c2aa5874ea3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.intimp.2020.106948$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids></links><search><creatorcontrib>Ma, Yubo</creatorcontrib><creatorcontrib>Fan, Dazhi</creatorcontrib><creatorcontrib>Xu, Shanshan</creatorcontrib><creatorcontrib>Deng, Jixiang</creatorcontrib><creatorcontrib>Gao, Xing</creatorcontrib><creatorcontrib>Guan, Shiyang</creatorcontrib><creatorcontrib>Pan, Faming</creatorcontrib><title>Calprotectin in spondyloarthritis: A systematic review and meta-analysis</title><title>International immunopharmacology</title><description>•Serum and fecal calprotectin were increased in SpA patients.•Level of serum or fecal calprotectin was associated with CRP, ESR, BASDAI and BASFI.•Serum and fecal calprotectin could act as biomarkers for SpA.
There is still an unmet need for a simple and reliable biomarker for diagnosis and disease activity of spondyloarthritis. Recent studies indicated that calprotectin could act as a biomarker for spondyloarthritis. Therefore, this systematic review and meta-analysis aims to evaluate the levels of serum and fecal calprotectin in spondyloarthritis and the associations with disease activity.
PubMed, Web of Science and Cochrane Library were comprehensively searched from inception to July 1st, 2019. The pooled standard mean differences (SMDs) were used to estimate the differences of the levels of serum and fecal calprotectin between spondyloarthritis patients and controls. Spearman correlation coefficients were used for evaluating the associations between the levels of serum and fecal calprotectin and disease activity of spondyloarthritis patients. The use of fixed-effect or random-effects model depended on heterogeneity.
Among 257 searched studies, 20 studies were finally included for analysis. Serum and fecal calprotectin were both significantly increased in spondyloarthritis patients compared to matched controls (SMD = 1.49, 95% CI = 0.91 to 2.08; SMD = 2.29, 95% CI = 0.25 to 4.33). The pooled correlation coefficients between serum or fecal calprotectin and CRP, ESR, BASDAI and BASFI were 0.353, 0.228, 0.225, 0.131 and 0.185, 0.163, 0.280, 0.196 respectively.
Our study indicated that serum and fecal calprotectin were significantly increased in spondyloarthritis patients, and associated with disease activity. Serum and fecal calprotectin were potential biomarkers for the diagnosis and disease activity of spondyloarthritis.</description><subject>Ankylosing spondylitis</subject><subject>Arthritis</subject><subject>Biomarkers</subject><subject>Calprotectin</subject><subject>Correlation coefficient</subject><subject>Correlation coefficients</subject><subject>Diagnosis</subject><subject>Feces</subject><subject>Heterogeneity</subject><subject>Inflammatory diseases</subject><subject>Meta-analysis</subject><subject>Rheumatic diseases</subject><subject>Spondyloarhritis</subject><subject>Systematic review</subject><issn>1567-5769</issn><issn>1878-1705</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kEtLAzEQgBdRsD7-gYcFL162Jpu3B0GKLxC86DlMkymm7KMmqdJ_b8p68iAMzDB8M8x8VXVByZwSKq_X8zDk0G_mLWn3LWm4PqhmVCvdUEXEYamFVI1Q0hxXJymtCSl9TmfV0wK6TRwzuhyGukTajIPfdSPE_BFDDummvqvTLmXsIQdXR_wK-F3D4OseMzQwQLdLIZ1VRyvoEp7_5tPq_eH-bfHUvLw-Pi_uXhrHpMoNtGwFginhQLdae2ak9ygQNTdLY5gAQOa908QLYhhfrqRi3LUAQiuOwE6rq2lvufpziynbPiSHXQcDjttkW86JlNwQWtDLP-h63MZy755SWrfUcFkoPlEujilFXNlNDD3EnaXE7vXatZ302r1eO-ktY7fTGJZni5Jokws4OPQhFpnWj-H_BT-Bd4WU</recordid><startdate>202011</startdate><enddate>202011</enddate><creator>Ma, Yubo</creator><creator>Fan, Dazhi</creator><creator>Xu, Shanshan</creator><creator>Deng, Jixiang</creator><creator>Gao, Xing</creator><creator>Guan, Shiyang</creator><creator>Pan, Faming</creator><general>Elsevier B.V</general><general>Elsevier BV</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>202011</creationdate><title>Calprotectin in spondyloarthritis: A systematic review and meta-analysis</title><author>Ma, Yubo ; Fan, Dazhi ; Xu, Shanshan ; Deng, Jixiang ; Gao, Xing ; Guan, Shiyang ; Pan, Faming</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c367t-a23fa5375ca8288d396dde5ee849b9935aae3ddc80d50934bf6734c2aa5874ea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Ankylosing spondylitis</topic><topic>Arthritis</topic><topic>Biomarkers</topic><topic>Calprotectin</topic><topic>Correlation coefficient</topic><topic>Correlation coefficients</topic><topic>Diagnosis</topic><topic>Feces</topic><topic>Heterogeneity</topic><topic>Inflammatory diseases</topic><topic>Meta-analysis</topic><topic>Rheumatic diseases</topic><topic>Spondyloarhritis</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ma, Yubo</creatorcontrib><creatorcontrib>Fan, Dazhi</creatorcontrib><creatorcontrib>Xu, Shanshan</creatorcontrib><creatorcontrib>Deng, Jixiang</creatorcontrib><creatorcontrib>Gao, Xing</creatorcontrib><creatorcontrib>Guan, Shiyang</creatorcontrib><creatorcontrib>Pan, Faming</creatorcontrib><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ma, Yubo</au><au>Fan, Dazhi</au><au>Xu, Shanshan</au><au>Deng, Jixiang</au><au>Gao, Xing</au><au>Guan, Shiyang</au><au>Pan, Faming</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Calprotectin in spondyloarthritis: A systematic review and meta-analysis</atitle><jtitle>International immunopharmacology</jtitle><date>2020-11</date><risdate>2020</risdate><volume>88</volume><spage>106948</spage><epage>106948</epage><pages>106948-106948</pages><artnum>106948</artnum><issn>1567-5769</issn><eissn>1878-1705</eissn><abstract>•Serum and fecal calprotectin were increased in SpA patients.•Level of serum or fecal calprotectin was associated with CRP, ESR, BASDAI and BASFI.•Serum and fecal calprotectin could act as biomarkers for SpA.
There is still an unmet need for a simple and reliable biomarker for diagnosis and disease activity of spondyloarthritis. Recent studies indicated that calprotectin could act as a biomarker for spondyloarthritis. Therefore, this systematic review and meta-analysis aims to evaluate the levels of serum and fecal calprotectin in spondyloarthritis and the associations with disease activity.
PubMed, Web of Science and Cochrane Library were comprehensively searched from inception to July 1st, 2019. The pooled standard mean differences (SMDs) were used to estimate the differences of the levels of serum and fecal calprotectin between spondyloarthritis patients and controls. Spearman correlation coefficients were used for evaluating the associations between the levels of serum and fecal calprotectin and disease activity of spondyloarthritis patients. The use of fixed-effect or random-effects model depended on heterogeneity.
Among 257 searched studies, 20 studies were finally included for analysis. Serum and fecal calprotectin were both significantly increased in spondyloarthritis patients compared to matched controls (SMD = 1.49, 95% CI = 0.91 to 2.08; SMD = 2.29, 95% CI = 0.25 to 4.33). The pooled correlation coefficients between serum or fecal calprotectin and CRP, ESR, BASDAI and BASFI were 0.353, 0.228, 0.225, 0.131 and 0.185, 0.163, 0.280, 0.196 respectively.
Our study indicated that serum and fecal calprotectin were significantly increased in spondyloarthritis patients, and associated with disease activity. Serum and fecal calprotectin were potential biomarkers for the diagnosis and disease activity of spondyloarthritis.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><doi>10.1016/j.intimp.2020.106948</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1567-5769 |
| ispartof | International immunopharmacology, 2020-11, Vol.88, p.106948-106948, Article 106948 |
| issn | 1567-5769 1878-1705 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2440664901 |
| source | Elsevier ScienceDirect Journals Complete |
| subjects | Ankylosing spondylitis Arthritis Biomarkers Calprotectin Correlation coefficient Correlation coefficients Diagnosis Feces Heterogeneity Inflammatory diseases Meta-analysis Rheumatic diseases Spondyloarhritis Systematic review |
| title | Calprotectin in spondyloarthritis: A systematic review and meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T20%3A50%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Calprotectin%20in%20spondyloarthritis:%20A%20systematic%20review%20and%20meta-analysis&rft.jtitle=International%20immunopharmacology&rft.au=Ma,%20Yubo&rft.date=2020-11&rft.volume=88&rft.spage=106948&rft.epage=106948&rft.pages=106948-106948&rft.artnum=106948&rft.issn=1567-5769&rft.eissn=1878-1705&rft_id=info:doi/10.1016/j.intimp.2020.106948&rft_dat=%3Cproquest_cross%3E2440664901%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2478821946&rft_id=info:pmid/&rft_els_id=S1567576920319548&rfr_iscdi=true |